avutometinib,everolimus
verastem
['vs-6766', 'everolimus']
today, the icr/ ' dr provides insights on the phase 1 trial testing the drugs vs-6766 and everolimus in patients with a range of mutations to #kras in the #asco22 poster discussion. 6th june 2022, 13:15 cdt. #asco22 
The Institute of Cancer Research is making the discoveries that defeat cancer. We're the UK's top academic research centre, a postgrad college, and a charity.